This product is produced by genetic recombination technology and is completely identical to human pituitary growth hormone in amino acid content, sequence and protein structure. In the field of pediatrics, the use of growth hormone replacement therapy can significantly promote height growth in children. At the same time, growth hormone also plays an important role in the field of reproduction, burns and anti-aging. It has been widely used in clinical practice.

1. For children with slow growth caused by endogenous growth hormone deficiency;
2. For children with short stature caused by Noonan syndrome;
3. It is used for children with short stature or growth disorder caused by lack of SHOX gene;
4. For children with short stature caused by achondroplasia;
5. For adults with short bowel syndrome receiving nutritional support;
6. For severe burn treatment;

1. Patients who are used for definite diagnosis under the guidance of a doctor.
2. Patients with diabetes may need to adjust the dose of antidiabetic drugs.
3. Simultaneous use of corticosteroids will inhibit the growth-promoting effect of growth hormone. Therefore, patients with ACTH deficiency should appropriately adjust the dosage of corticosteroids to avoid their inhibitory effect on growth hormone production.
4. A small number of patients may have hypothyroidism during the treatment of growth hormone, which should be corrected in time to avoid affecting the efficacy of growth hormone. Therefore, patients should regularly check thyroid function and give thyroxine supplementation if necessary.
5. Patients with endocrine diseases (including growth hormone deficiency) may have slipped femoral head epiphysis, and should pay attention to evaluation if claudication occurs during the treatment period of growth hormone.
6. Sometimes growth hormone can lead to excessive insulin state, so it is necessary to pay attention to whether the patient has the phenomenon of impaired glucose tolerance.
7. During the treatment period, if the blood sugar is higher than 10mmol/L, insulin treatment is required. If the blood sugar cannot be effectively controlled with more than 150IU/day of insulin, this product should be discontinued.
8. Growth hormone is injected subcutaneously, and the parts that can be selected are around the navel, upper arm, outer thigh, and buttocks. The injection of growth hormone needs to change the site frequently to prevent subcutaneous fat atrophy caused by injection in the same site for a long time. If injecting at the same site, pay attention to the interval of more than 2cm between each injection site.

1. Growth-promoting therapy is contraindicated after the epiphysis has been completely closed.
2. In critically ill patients such as severe systemic infection, it is disabled during the acute shock period of the body.
3. Those who are known to be allergic to growth hormone or its protective agents are prohibited.
4. Contraindicated in patients with active malignant tumors. Any pre-existing malignancy should be inactive and tumor treatment completed prior to growth hormone therapy. Growth hormone therapy should be discontinued if there is evidence of a risk of tumor recurrence. Since growth hormone deficiency may be an early sign of the presence of pituitary tumors (or other rare brain tumors), such tumors should be ruled out before treatment. Growth hormone should not be used in any patient with underlying intracranial tumor progression or recurrence.
5. It is contraindicated in the following acute and critically ill patients with complications: open heart surgery, abdominal surgery or multiple accidental trauma.
6. Disabled when acute respiratory failure occurs.
7. Patients with proliferative or severe non-proliferative diabetic retinopathy are disabled.